Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells.
- Author:
Yu-qing GE
;
Ru-bin CHENG
;
Bo YANG
;
Zhen HUANG
;
Zhe CHEN
- Publication Type:Journal Article
- MeSH:
ATP-Binding Cassette, Sub-Family B, Member 1;
genetics;
metabolism;
Antineoplastic Agents;
pharmacology;
Apoptosis;
drug effects;
Caspase 3;
genetics;
metabolism;
Caspase 9;
genetics;
metabolism;
Drug Resistance, Neoplasm;
drug effects;
Drugs, Chinese Herbal;
pharmacology;
Humans;
Imatinib Mesylate;
pharmacology;
K562 Cells;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
genetics;
metabolism;
physiopathology;
Phenanthrenes;
pharmacology
- From:
China Journal of Chinese Materia Medica
2015;40(12):2389-2395
- CountryChina
- Language:Chinese
-
Abstract:
Cryptotanshinone (CPT), a lipid soluble active compound in Salvia miltiorrhiza, has a significant inhibitory effect on multiple malignant tumors, e. g. chronic myeloid leukemia (CML) cells and can effectively enhance imatinib's chemotherapeutic effect. However, its functional molecular mechanism remained unclear. In this experiment, the authors conducted a systematic study on the effect of CPT on the imatinib sensitivity and P-glycoprotein (P-gp) expression in CML cells by using CML cells K562 and imatinib persister K562-R. The MTT assays were performed to determine CPT's impact on the inhibitory effect of imatinib. Annexin V-FITC/PI staining analysis was used to detect the changes in the cell apoptosis rate. The active changes in apoptosis regulatory proteins Caspase-3, Caspase-9 and PARP were determined by Western blot. After the cells were pretreated with the gradient concentration of CPT, the expression of P-gp was analyzed by Western blot and flow cytometry. The changes in intracellular concentrations of imatinib were determined by HPLC analysis. The results indicated that the pretreatment with CPT significantly increased the proliferation inhibiting and apoptosis inducing effects of imatinib on K562 and K562-R cells as well as the degradation product expression of pro-apoptotic proteins Caspase-3, Caspase-9 and PARP, with a significant difference with the control group (P < 0.01). However, CPT showed no impact on the P-gp expression in CML cells and the intracellular concentrations of imatinib. In summary, the findings suggested that CPT enhanced the sensitivity of CML cells to imatinib. Its mechanism is not dependent on the inhibition in P-gp expression and the increase in intracellular drug concentration.
